Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 223 results for heart attack

  1. Erectile dysfunction: avanafil (ESNM45)

    Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

    Evidence summary
    Published
    12 August 2014

  2. Further research on implanting a baroreceptor stimulation device for resistant hypertension should document patient selection in detail and should specify the devices and techniques used, and any adjunctive therapies. It should describe the changes in blood pressure that are considered to result from baroreceptor stimulation, and those that might be caused by other factors. Outcomes should include the duration of effect of baroreceptor stimulation; device durability; and the complications of hypertension, such as myocardial infarction and stroke.

    device durability; and the complications of hypertension, such as myocardial infarction and stroke. Any explanatory notes(if applicable)...

    Research recommendation
    Published
    9 December 2015

  3. Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

    Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

    Evidence summary
    Published
    24 September 2013

  4. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued Reference number: GID-TAG493

    Technology appraisal guidance
    Discontinued

  5. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

    NICE guideline
    Published
    6 July 2016
    View recommendations

    Sections for NG49

  6. Non-surgical reduction of the myocardial septum (HTG18)

    Evidence-based recommendations on non-surgical reduction of myocardial septum. This involves inserting a catheter into the femoral artery and passing it up into the heart under X-ray control.

    HealthTech guidance
    Published
    25 February 2004
    View recommendations

    Sections for HTG18

  7. High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery (HTG119)

    Evidence-based recommendations on high-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery. This involves using focused ultrasound energy to destroy cardiac tissue and disrupt abnormal electrical impulses.

    HealthTech guidance
    Published
    26 July 2006
    View recommendations

    Sections for HTG119

  8. Heart valve disease presenting in adults: investigation and management (NG208)

    This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.

    NICE guideline
    Published
    17 November 2021
    View recommendations

    Sections for NG208

  9. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (HTG553)

    Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke.

    HealthTech guidance
    Published
    2 September 2020
    View recommendations

    Sections for HTG553

  10. Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)

    Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA814

  11. HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (HTG429)

    Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography.

    HealthTech guidance
    Last updated
    19 May 2021
    View recommendations

    Sections for HTG429

  12. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.

    Technology appraisal guidance
    Last updated
    1 December 2012
    View recommendations

    Sections for TA197

  13. Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting (HTG415)

    Evidence-based recommendations on transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting in adults. This involves reversing blood flow away from the brain and filtering the blood to remove any debris.

    HealthTech guidance
    Published
    22 June 2016
    View recommendations

    Sections for HTG415

  14. Balloon valvuloplasty for aortic valve stenosis in adults and children (HTG49)

    Evidence-based recommendations on balloon valvuloplasty for aortic valve stenosis in adults and children. This involves inflating a balloon inserted into the narrow valve to widen it so that blood can flow out more easily.

    HealthTech guidance
    Published
    28 July 2004
    View recommendations

    Sections for HTG49

  15. Into practice resources

    Resources, case studies and patient decision aids to show how you can use evidence to improve care and services